Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Analysts

Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT) have been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $31.00.

Several research firms have recently commented on MPLT. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $32.00 price target for the company. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. Leerink Partnrs upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Friday, November 21st. Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Stifel Nicolaus initiated coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price objective on the stock.

Maplight Therapeutics Stock Down 7.5%

Shares of NASDAQ:MPLT opened at $17.64 on Friday. Maplight Therapeutics has a one year low of $12.24 and a one year high of $21.55. The stock has a market capitalization of $800.33 million and a PE ratio of -0.47. The company has a 50-day simple moving average of $16.77.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.